Iterum Therapeutics plc reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net income was USD 3.74 million compared to net loss of USD 12.2 million a year ago. Basic earnings per share from continuing operations was USD 0.3 compared to basic loss per share from continuing operations of USD 9 a year ago. Diluted earnings per share from continuing operations was USD 0.3 compared to diluted loss per share from continuing operations of USD 9 a year ago.
For the nine months, net loss was USD 87.38 million compared to USD 40.82 million a year ago. Basic loss per share from continuing operations was USD 8.4 compared to USD 35.85 a year ago. Diluted loss per share from continuing operations was USD 8.4 compared to USD 35.85 a year ago.